Sagimet Biosciences
SGMT
67 hedge funds and large institutions have $89M invested in Sagimet Biosciences in 2025 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 11 increasing their positions, 14 reducing their positions, and 27 closing their positions.
98% more capital invested
Capital invested by funds: $44.9M → $89M (+$44.1M)
77% more call options, than puts
Call options by funds: $3.95M | Put options by funds: $2.24M
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
4% less funds holding
Funds holding: 70 → 67 (-3)
6.84% less ownership
Funds ownership: 44.9% → 38.06% (-6.8%)
11% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 27
21% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$10.8M |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$1.22M |
| 3 |
RAM
Readystate Asset Management
Chicago,
Illinois
|
+$1.14M |
| 4 |
JF
Jump Financial
Chicago,
Illinois
|
+$626K |
| 5 |
D.E. Shaw & Co
New York
|
+$607K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$5.72M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$3.89M |
| 3 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$2.57M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$2.36M |
| 5 |
BlackRock
New York
|
-$2.06M |
SGMT Hedge Fund Activity: Q2 2025 in Review
67 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Sagimet Biosciences (SGMT) for Q2 2025, worth a combined $89M — up 98% from $44.9M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of SGMT and 24 opened new positions — a net loss of 3 holders — while 14 trimmed existing stakes and 11 added.
The largest buyer was Woodline Partners, opening a new position worth an estimated $10.8M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $5.72M sold.
- 67 institutional investors held Sagimet Biosciences (SGMT) as of Q2 2025, down from 70 in Q1 2025.
- Funds reported $89M of Sagimet Biosciences stock for Q2 2025, up 98% quarter-over-quarter.
- 24 funds opened new Sagimet Biosciences positions in Q2 2025 and 27 closed out, a net change of -3 holders.
- The largest Sagimet Biosciences buyer in Q2 2025 was Woodline Partners, an estimated $10.8M added.
- The largest Sagimet Biosciences seller in Q2 2025 was Point72 Asset Management, an estimated $5.72M sold.
Based on aggregated 13F filings for Q2 2025.